1) Takahashi K, Saito K, Takahara S, et al, IDEC-C2B8 ABO-I KTx Study Group:Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation. Clin Exp Nephrol 2017;21(4):705-13 2) Chow KV, Flint SM, Shen A, et al:Histological and extended clinical outcomes after ABO-incompatible renal transplantation without splenectomy or rituximab. Transplantation 2017;101(6):1433-40 3) Masutani K, Tsuchimoto A, Kurihara K, et al, Japan Academic Consortium of Kidney Transplantation(JACK)investigators:Histological analysis in ABO-compatible and ABO-incompatible kidney transplantation by performance of 3- and 12-month protocol biopsies. Transplantation 2017;101(6):1416-22 4) Kauke T, Klimaschewski S, Schoenermarck U, et al:Outcome after desensitization in HLA or ABO-incompatible kidney transplant recipients:A single center experience. PLoS One 2016;11(1):e0146075 5) Gelpi R, Cid J, Lozano M, et al:Desensitization in ABO-incompatible kidney transplantation with Low ABO iso-agglutinin titers. Transplant Proc 2015;47(8):2340-3 6) Won DI, Ham JY, Kim CD, et al:Benefits of fresh-frozen plasma as a replacement fluid to neutralize ABO antibodies. J Clin Apher 2015;30(5):288-96 7) de Weerd AE, van Agteren M, Leebeek FW, et al:ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption. Transpl Int 2015;28(1):25-33 8) Opelz G, Morath C, Susal C, et al:Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction:results from 101 centers. Transplantation 2015;99(2):400-4 9) Shishido S, Hyodo YY, Aoki Y, et al:Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls. Transplant Proc 2012;44(1):214-6 10) Lawrence C, Galliford JW, Willicombe MK, et al:Antibody removal before ABO-incompatible renal transplantation:how much plasma exchange is therapeutic? Transplantation 2011;92(10):1129-33 11) Tyden G, Kumlien G, Berg UB:ABO-incompatible kidney transplantation in children. Pediatr Transplant 2011;15(5):502-4 12) Chung BH, Lee JY, Kang SH, et al:Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Ren Fail 2011;33(2):150-8 13) Fuchinoue S, Ishii Y, Sawada T, et al:The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011;91(8):853-7 14) Wilpert J, Fischer KG, Pisarski P, et al:Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010;25(11):3778-86 15) Tobian AA, Shirey RS, Montgomery RA, et al:ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010;10(5):1247-53 16) Sivakumaran P, Vo AA, Villicana R, et al:Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. J Clin Apher 2009;24(4):155-60 17) Tobian AA, Shirey RS, Montgomery RA, et al:Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion 2009;49(6):1248-54 18) Genberg H, Kumlien G, Wennberg L, et al:ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab:a 3-year follow-up. Transplantation 2008;85(12):1745-54 19) Tyden G, Donauer J, Wadstrom J, et al:Implementation of a Protocol for ABO-incompatible kidney transplantation―a three-center experience with 60 consecutive transplantations. Transplantation 2007;83(9):1153-5 20) Tanabe K:Double-filtration plasmapheresis. Transplantation 2007;84(12 Suppl):S30-2 21) Segev DL, Simpkins CE, Warren DS, et al:ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005;5(10):2570-5 22) Tydén G, Kumlien G, Genberg H, et al:ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005;5(1):145-8